Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Monte Rosa Therapeutics, Inc. (GLUE) had Normalized Pre-Tax Income of $-44.45M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$4.21M |
|
$-44.50M |
|
-- |
|
$4.21M |
|
$54.24M |
|
$-50.03M |
|
$5.58M |
|
$-44.45M |
|
|
Normalized Pre-Tax Income |
$-44.45M |
$-44.50M |
|
$-44.50M |
|
$-44.50M |
|
$-44.50M |
|
$-50.03M |
|
$-48.01M |
|
99.88M |
|
99.88M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$677.55M |
|
$28.41M |
|
$58.88M |
|
$736.43M |
|
$71.04M |
|
-- |
|
$143.48M |
|
$214.51M |
|
$521.92M |
|
$521.92M |
|
$521.92M |
|
84.32M |
|
| Cash Flow Statement Financials | |
$-37.37M |
|
$-261.00M |
|
$328.33M |
|
$134.84M |
|
$164.81M |
|
$29.97M |
|
$5.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1188.46% |
|
-1188.46% |
|
-- |
|
-1055.84% |
|
-1057.08% |
|
$-39.24M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.91 |
|
98.53 |
|
-8.53% |
|
-8.53% |
|
-6.04% |
|
-8.53% |
|
$6.19 |
|
$-0.39 |
|
$-0.37 |
|